938 Mass spectrometry period of 15 min. All solvents were degassed before use by sparging with helium. References Mass spectrometric data was acquired with a Finnigan TSQ7000 triple-stage-quadrupole instrument fitted with an APCI API2 probe and interfaced with an APCI/ESI controller unit. The vaporizer and heated capillary temper- atures were maintained at 450°C and 150°C, respectively, and the corona voltage was set at 4 kV. The nitrogen sheath gas pressure was 60 psi; however, the auxiliary gas function was not used. The low mass (0–2,000 amu) range was selected. For recording data in the fullscan mode, the mass spectrometer was scanned from 100 to 650 amu with a scan time of 0.5 s. For MS/MS analyses, the argon gas pressure in the collision cell was set to 2.6 mTorr. Quantitative analyses were carried out in the selected reaction monitor- ing mode, with the following transitions being monitored: m/z 433 to m/z 373 for salvinorin A; m/z 436 to m/z 373 for salvinorin B; m/z 436 to m/z 376 for salvinorin A-d3; and m/z 439 to m/z 376 for salvinorin B-d3. The resolution was set to 0.6 amu and the scan times to 0.25 s. The collision energy for each transition was 15 V. Prepared dose stability testing Finnigan Xcalibur/LC Quan software was used to generate the calibration curves (non-linear regression, 1/X weighting) and calculate concentrations using peak-height ratios of analyte/ internal standard. Standard curves were generated from 0 to 2,000 ng/mL. A concentration of salvinorin A in DMSO–PEG-400 (25:75, v/v) of 4.00 mg/mL should calculate to 1,000 ng/ mL. The following results were obtained: Found concentration (ng/mL) Equivalent concentration in DMSO-PEG 400 (ng/mL) 915 915 891 894 1. 2. 1. 2. Freshly prepared solution Six-day-old solution 3.66 3.66 3.56 3.59 The results of the analyses indicate a 1% difference between the calculated values for the two sets of samples, which is statistically insignificant. The analyses also detected trace amounts of the hydrolysis product, salvinorin B, in both samples. Psychopharmacology (2011) 214:933–939 Addy PH (2010) That deep internal voice: controlled administration of Salvia divinorum clinical psychology. Institute of Transpersonal Psychology, Palo Alto Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum in 500 users. Drug Alcohol Depend 111:250–256 Breton J, Huynh C, Raymond S, Labelle R, Bonnet N, Cohen D, Guilé J (2010) Prolonged hallucinations and dissociative self mutilation following use of Salvia divinorum in a bipolar adolescent girl. J Subs Use 15:113–117 Butelman ER, Harris TJ, Kreek MJ (2004) The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172:220–224 Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440–447 Coyerly J, Peters L, Whittle E, Basketter DA (1998) Susceptibility to skin stinging, non-immunologic contact urticaria and acute skin irritation; is there a relationship? Wiley, New York, pp 90–95 Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacop- sychiatry 31(Suppl 2):80–84 Fantegrossi WE, Kugle KM, Valdes LJ III, Koreeda M, Woods JH (2005) Kappa-opioid receptor-mediated effects of the plant- derived hallucinogen, salvinorin A, on inverted screen perfor- mance in the mouse. Behav Pharmacol 16:627–633 González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157–162 Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3, 4- methylenedioxymethamphetamine (MDMA) in humans. Psycho- pharmacology (Berl) 162:396–405 Katz MM, Waskow IE, Olsson J (1968) Characterizing the psychological state produced by LSD. J Abnorm Psychol 73:1–14 Keung WM, Lazo O, Kunze L, Vallee BL (1996) Potentiation of the bioavailability of daidzin by an extract of Radix puerariae. Proc Natl Acad Sci USA 93:4284–4288 Munro TA (2006) The chemistry of Salvia divinorum chemistry. University of Melbourne, Melbourne Munro TA, Rizzacasa MA (2003) Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A. J Nat Prod 66:703–705 Ortega A, Blount JF, Manchand PD (1982) Salvinorin, a new trans- neoclerodane diterpene from Salvia divinorum (Labiatae). J Chem Soc Perkins Trans 1:2505–2508 Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103–129 Ott J (1996) Salvia divinorum Epling et Játiva (Foglie della Pastora/ Leaves of the Sheperdess). Eleusis 4:31–39 Paulzen M, Grunder G (2008) Toxic psychosis after intake of the hallucinogen salvinorin A. J Clin Psychiatry 69:1501 Pavarin RM (2006) Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy. Ann Ist Super Sanità 42:477–484 Przekop P, Lee T (2009) Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 166:832 Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally